Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3232 - Retrospective analysis of metastatic non-clear cell renal carcinoma (NCCRC): the Spanish Grupo Centro Experience


09 Oct 2016


Poster display


Laura Rodriguez Lajusticia


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


L. Rodriguez Lajusticia1, A. Martín2, A. Pinto Marin3, C. Aguado4, T. Alonso Gordoa5, A. Herrero6, C. Maximiano7, M. Garrido Arevalo8, I. Gallegos9, L. Villalobos10, J. Cassinello11, I. Garcia12, J. Espinosa Arranz13, J. Garcia-Donas14, J.J. Tafalla15, G. Torres6, J. Puente16, E. Grande Pulido5

Author affiliations

  • 1 Medical Oncology, Hospital Universitario de Fuenlabrada, 28942 - Fuenlabrada/ES
  • 2 Medical Oncology, Hospital Infanta Leonor, 28031 - Vallecas/ES
  • 3 Medical Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 4 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 5 Medical Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 6 Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 7 Medical Oncology, Hospital Universitario Puerta de Hierro, 28222 - Madrid/ES
  • 8 Medical Oncology, Hospital Universitario Severo Ochoa, 28911 - Leganés/ES
  • 9 Medical Oncology, Hospital General Segovia, Segovia/ES
  • 10 Medical Oncology, Hospital Universitario Príncipe de Asturias, Alcalá de Henares/ES
  • 11 Medical Oncology, Hospital Universitario de Guadalajara, 19002 - Guadalajara/ES
  • 12 Medical Oncology, Hospital Virgen de la Salud, Toledo/ES
  • 13 Medical Oncology, Hospital General Ciudad Real, Ciudad Real/ES
  • 14 Medical Oncology, CIOCC-Fundacion Hospital de Madrid, Madrid/ES
  • 15 Medical Oncology, Hospital La Luz, Madrid/ES
  • 16 Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid/ES


Abstract 3232


Non-clear cell renal carcinoma (NCCRC) represents a group of multiple histologic subtypes, with different clinical outcomes and uncertain optimal treatment. Due to the unfrequency of these histologies, they are usually grouped as one and treated the same way as clear cell renal carcinoma.


We performed a retrospective, multicenter study including patients (pts) with metastatic NCCRC diagnosed between 1995 and 2015. Data were collected from medical records at 14 hospitals. We evaluated the baseline clinical features, histologic subtypes, therapeutic management and survival status.


We collected a total of 173 patients, with a median age at diagnosis of 65 years [24-90], 67.1% men, and 85.5% had undergone nephrectomy. Histologic subtypes were 55.5% papillary carcinoma, 13.9% chromophobe, 0,6% oncocytoma, 23.1% sarcomatoid and 6.9% unclassified tumours. Assignment according to MSKCC risk groups were: 21.4% favourable, 53.8% intermediate, 20.2% poor, 4.6% unknown. 62.4% pts recieved tirosyne kinase inhibitors (TKI) as first line (82.4% sunitinib, 9.3% pazopanib and 8.3% sorafenib), 11% mammalian target of rapamycin inhibitors (mTORI: 89.5% temsirolimus), 6.9% chemotherapy, 5.8% inmunotherapy and 4% local treatment. Only 8.1% pts did not recived any kind of treatment. Response rate (RR) in evaluable pts (142) were: complete 5.6% pts, partial 17.6%, stable disease 40.8% and progression in 35.9%. 59.5% pts had discontinued treatment due to progression and 13.3% due to toxicity. 90 pts recieved a second line of treatment, most of them TKI (50%). 30% pts were treated with everolimus. At the time of data cut-off (April 1, 2016), 125 pts had died, with a median overall survival (OS) of 11 months (m) [1-73]. OS according to histology: papillary 18 m, chromophobe 16 m, sarcomatoid 5m and unclassified 5m. Favourable prognosis NCCRC pts lived longer than intermediate or poor prognosis ones (32 m vs 11 m vs 5.5m).


Clinical outcome reported in this study shows lower RR and OS than published by other authors, probably due to the high percentage of sarcomatoid and poor prognosis tumours in this population. In view of these results, further research is needed in this area

Clinical trial identification

Legal entity responsible for the study

Spanish Grupo Centro


Spanish Grupo Centro


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings